UB Paderborn / Katalog / Suche / in CDI

Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein

PLoS pathogens, 2013-04, Vol.9 (4), p.e1003302-e1003302

2013

Link zum Volltext

Verfügbarkeit prüfen

SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency

Cell host & microbe, 2017-05, Vol.21 (5), p.569-579.e6

2017

Link zum Volltext

Verfügbarkeit prüfen

Rab7A is required for efficient production of infectious HIV-1

PLoS pathogens, 2011-11, Vol.7 (11), p.e1002347-e1002347

2011

Link zum Volltext

Verfügbarkeit prüfen

P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

Annals of hepatology, 2023-03, Vol.28, p.100905, Article 100905

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19

Clinical and translational science, 2023-06, Vol.16 (6), p.1049-1062

2023

Link zum Volltext

Verfügbarkeit prüfen

Endosomal Trafficking of HIV-1 Gag and Genomic RNAs Regulates Viral Egress

The Journal of biological chemistry, 2009-07, Vol.284 (29), p.19727-19743

2009

Link zum Volltext

Verfügbarkeit prüfen

The clathrin adaptor complex AP-1 binds HIV-1 and MLV Gag and facilitates their budding

Molecular biology of the cell, 2007-08, Vol.18 (8), p.3193-3203

2007

Link zum Volltext

Verfügbarkeit prüfen

Lipid Droplet-Binding Protein TIP47 Regulates Hepatitis C Virus RNA Replication through Interaction with the Viral NS5A Protein: e1003302

PLoS pathogens, 2013-04, Vol.9 (4)

2013

Link zum Volltext

Verfügbarkeit prüfen

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

The New England journal of medicine, 2022-01, Vol.386 (4), p.305-315

2022

Link zum Volltext

Verfügbarkeit prüfen

Tail-Interacting Protein TIP47 Is a Connector between Gag and Env and Is Required for Env Incorporation into HIV-1 Virions

Proceedings of the National Academy of Sciences - PNAS, 2006-10, Vol.103 (40), p.14947-14952

2006

Link zum Volltext

Verfügbarkeit prüfen

How the antiviral immune response boosts liver fat

Nature medicine, 2013-06, Vol.19 (6), p.671-672

2013

Link zum Volltext

Verfügbarkeit prüfen

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Journal of hepatology, 2017-08, Vol.67 (2), p.224-236

2017

Link zum Volltext

Verfügbarkeit prüfen

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

Antimicrobial agents and chemotherapy, 2022-06, Vol.66 (6), p.e0022222-e0022222

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

Gastroenterology (New York, N.Y. 1943), 2018-10, Vol.155 (4), p.1120-1127.e4

2018

Link zum Volltext

Verfügbarkeit prüfen

Diacylglycerol Acyltransferase-1 Localizes Hepatitis C Virus NS5A Protein to Lipid Droplets and Enhances NS5A Interaction with the Viral Capsid Core

The Journal of biological chemistry, 2013-04, Vol.288 (14), p.9915-9923

2013

Link zum Volltext

Verfügbarkeit prüfen

OS-031 - Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial

Journal of hepatology, 2023-06, Vol.78, p.S34-S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial

Journal of hepatology, 2023-06, Vol.78, p.S34-S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients

Journal of hepatology, 2018-09, Vol.69 (3), p.603-607

2018

Link zum Volltext

Verfügbarkeit prüfen

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients

Journal of hepatology, 2018-12, Vol.69 (6), p.1221-1230

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

Gastroenterology (New York, N.Y. 1943), 2018-03, Vol.154 (4), p.989-997

2018

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

Journal of clinical microbiology, 2019-04, Vol.57 (4)

2019

Link zum Volltext

Verfügbarkeit prüfen

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

The Journal of infectious diseases, 2023-11, Vol.228 (9), p.1263-1273

2023

Link zum Volltext

Verfügbarkeit prüfen

Correction for Han et al., “ In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir”

Journal of clinical microbiology, 2020-06, Vol.58 (7)

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

The American journal of gastroenterology, 2024-03, Vol.119 (3), p.486-496

2024

Link zum Volltext

Verfügbarkeit prüfen

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial

The lancet. Gastroenterology & hepatology, 2019-02, Vol.4 (2), p.119-126

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein

SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency

Rab7A is required for efficient production of infectious HIV-1

P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19

Endosomal Trafficking of HIV-1 Gag and Genomic RNAs Regulates Viral Egress

The clathrin adaptor complex AP-1 binds HIV-1 and MLV Gag and facilitates their budding

Lipid Droplet-Binding Protein TIP47 Regulates Hepatitis C Virus RNA Replication through Interaction with the Viral NS5A Protein: e1003302

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Tail-Interacting Protein TIP47 Is a Connector between Gag and Env and Is Required for Env Incorporation into HIV-1 Virions

How the antiviral immune response boosts liver fat

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

Diacylglycerol Acyltransferase-1 Localizes Hepatitis C Virus NS5A Protein to Lipid Droplets and Enhances NS5A Interaction with the Viral Capsid Core

OS-031 - Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial

Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial

Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

Correction for Han et al., “ In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir”

Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial

Suchergebnisse filtern